Key Highlights: Implications: Viatris is selling up to 92 million Biocon shares (about 5.6% of the company) in a secondary sale, so Biocon gets no money from it; the deal is priced at a di...
Key Highlights: Implications: Pivot Path’s majority sale to an Ascent-led consortium effectively spins it out as an independent, PE-backed specialist, which should accelerate its growth in...
